Skip to content
  • Contact Us
  • Request Samples
  • Order
Mill Creek Life Sciences
  • Our Technology
    • Human Platelet Lysate
    • Applications
    • Dendritic Cell Vaccine
  • Products
    • PLTMax®
    • PLTGold®
    • Order
    • Request Samples
  • Support
    • Technical Support
    • Publications
    • Posters
    • Distributors
    • FAQs
    • Contact Us
  • About Us
    • Our Company
    • Quality
    • News
    • Collaborate
    • Careers
Filters (5)
Filters
  • Reset all ×
  • 2022 ×

5 resources found

Show (5)
Cancel

Phase I trial of adjuvant mature autologous dendritic cell/allogeneic tumor lysate vaccines in combination with temozolomide in newly diagnosed glioblastoma (Jun 2022)

Marrow-Derived Autologous Stromal Cells for the Restoration of Salivary Hypofunction (MARSH): Study protocol for a phase 1 dose-escalation trial of patients with xerostomia after radiation therapy for head and neck cancer: MARSH: Marrow-Derived Autologous Stromal Cells for the Restoration of Salivary Hypofunction (Oct 2022)

Hydrogel supplemented with human platelet lysate enhances multi-lineage differentiation of mesenchymal stem cells (Apr 2022)

Normal ex vivo mesenchymal stem cell function combined with abnormal immune profiles sets the stage for informative cell therapy trials in idiopathic pulmonary fibrosis patients (Jan 2022)

Human meniscus allograft augmentation by allogeneic mesenchymal stromal/stem cell injections (Mar 2022)

MillCreekLifeSciences_StackedWhite-01

221 1st Avenue SW, Suite 209 Rochester, Minnesota 55902, USA

Phone: 507-287-6257
Fax: 507-289-2066
Email: info@millcreekls.com

OUR TECHNOLOGY

Human Platelet Lysate

Applications

Dendritic Cell Vaccine

PRODUCTS

PLTMax®

PLTGold®

Order

Request Samples

SUPPORT

Technical Support

Publications

Posters

Distributors

FAQs

Contact Us

ABOUT US

Our Company

Quality

News

Collaborate

Careers